Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Effects on Renal Morphology and Perfusion After Kidney Transplantation
2024-517885-40-00Phase 4Authorised
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Renal morphology and tissue markers (primary). Planned start Sep 2024; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-517885-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517885-40-00.